Extracorporeal Life Support in Lung Transplantation
Extracorporeal Life Support in Lung Transplantation
复制标题
DOI：
10.1016/j.ccm.2017.07.006
复制
发表时间：
2017-12-01
影响因子：
5.7
通讯作者：
Arcasoy, Selim M.
中科院分区：
文献类型：
--
作者：
Abrams, Darryl;Brodie, Daniel;Arcasoy, Selim M.
肺移植的体外生命支持与移植后的不良结果有关。然而，最近的进展导致了更有利的移植后结果。必须权衡这项技术的增加使用与其使用所固有的风险，特别是当体外膜氧合(ECMO)依赖患者出现并发症导致失去移植候选资格时，使他们没有可行的长期支持选择。现有的和新兴的数据支持在大容量移植和ECMO中心精心挑选的患者中明智地使用这项技术，这些中心优先考虑最大限度地减少镇静、避免气管插管和早期动员。
Extracorporeal life support in lung transplantation has been associated with poor posttransplant outcomes. However, recent advances have resulted in more favorable posttransplant outcomes. The increased use of this technology must be weighed against the risks inherent in its use, especially when complications arising in extracorporeal membrane oxygenation (ECMO)-dependent patients result in loss of transplant candidacy, leaving them with no viable alternative for long-term support. Existing and emerging data support the judicious use of this technology in carefully selected patients at high-volume transplant and ECMO centers that prioritize minimization of sedation, avoidance of endotracheal intubation, and early mobilization.